DOI QR코드

DOI QR Code

Prostate Cancer Epidemiology in a Rural Area of North Western Greece

  • Grivas, N. (Department of Urology, "Hatzikosta" General Hospital of ioannina) ;
  • Hastazeris, K. (Department of Urology, "Hatzikosta" General Hospital of ioannina) ;
  • Kafarakis, V. (Department of Urology, "Hatzikosta" General Hospital of ioannina) ;
  • Tsimaris, I. (Department of Urology, "Hatzikosta" General Hospital of ioannina) ;
  • Xousianitis, Z. (Department of Urology, "Hatzikosta" General Hospital of ioannina) ;
  • Makatsori, A. (Department of Urology, "Hatzikosta" General Hospital of ioannina) ;
  • Raptis, P. (Department of Urology, "Hatzikosta" General Hospital of ioannina) ;
  • Aspiotis, S. (Department of Urology, "Hatzikosta" General Hospital of ioannina) ;
  • Ioachim, E. (Department of Pathology, "Hatzikosta" General Hospital of ioannina) ;
  • Ntemou, A. (Department of Pathology, "Hatzikosta" General Hospital of ioannina) ;
  • Kitsiou, E. (Department of Pathology, "Hatzikosta" General Hospital of ioannina) ;
  • Malamou-Mitsi, V. (Department of Pathology, University Hospital of ioannina) ;
  • Sofikitis, N. (Department of Urology, University Hospital of ioannina) ;
  • Kordela, V. (Department of Pathology, General Hospital of Preveza) ;
  • Papandreou, C. (Department of Urology, General Hospital of Arta) ;
  • Agnantis, N.J. (Department of Pathology, University Hospital of ioannina) ;
  • Stavropoulos, N.E. (Department of Urology, "Hatzikosta" General Hospital of ioannina)
  • Published : 2012.03.31

Abstract

Epirus is a rural area of North-Western Greece. We reviewed data from 4 hospitals for 4.975 patients who underwent prostate biopsy in Epirus in the twelve year period from 1999 to 2010. Two six -year periods were compared (1999-2004 and 2004-2010). All cases of prostate cancer confirmed by biopsy were recorded and age-standardized incidence rates per 100,000 males were calculated. We also recorded the clinical stage for patients diagnosed in our hospital and correlated this with PSA and Gleason scores. Percentage of positive prostate biopsies was also calculated. There were a total of 1714 new cases during 1999-2010 and the mean annual age-adjusted incidence was 34/100.000. The mean incidences during 1999-2004 and 2005-2010 were 26/100,000 and 42/100,000, respectively. The mean age at diagnosis was 74. The most common Gleason score was 6 and the prevalent clinical stage was T2. Median PSA at diagnosis was 10.8 ng/ml. There was a significant difference between stage cT4 and all other stages regarding PSA value (p=0.000). A positive correlation was found between Gleason score and PSA (p=0.013). These results are in accordance with the incidence rise recorded in neighboring countries of South-East Europe. However we should keep in mind the risk of overdiagnosis and the detection of low-risk cancers that would not have caused morbidity or death during a man's lifetime anyway.

References

  1. Boyle P, Severi G, Giles GG (2003). The epidemiology of prostate cancer. Urol Clin North Am, 30, 209-17. https://doi.org/10.1016/S0094-0143(02)00181-7
  2. Bioteach. Assessed 14 December 2005 www.bioteach.ubc.ca/Biomedicine/ProstateCancer/
  3. CA: A Cancer Journal for Clinicians 61:Issue 2, MARCH/APRIL 2011. Article first published online: 4 FEB 2011. Available online at http://cajournal.org and http://cacancerjournal.org.
  4. Chou Roger, Croswel M Jennifer, Dana Tracy, et al (2011). screening for prostate cancer: A review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med, 155,762-71. https://doi.org/10.7326/0003-4819-155-11-201112060-00375
  5. Ferlay J, Shin HR, Bray F, et al (2010). GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet].IARC, Lyon.
  6. Higginbotham JC, Moulder J, Currier M (2001). Rural v. urban aspects of cancer: first-year data from the Mississippi Central Cancer Registry. Fam Community Health, 24, 1-9.
  7. Larranaga N, Galceran J, Ardanaz E, et al (2010). Prostate cancer incidence trends in Spain before and during the prostatespecific antigen era: impact on mortality. Ann Oncol, 21, 83-9
  8. McLafferty S, Wang F (2009). Rural reversal? Rural-urban disparities in late-stage cancer risk in Illinois. Cancer, 115, 2755-64. https://doi.org/10.1002/cncr.24306
  9. Merrill RM, Feuer EJ, Warren JL et al (1999). Role of transurethral resection of the prostate in population-based prostate cancer incidence rates. Am J Epidemiol, 150, 848- 60. https://doi.org/10.1093/oxfordjournals.aje.a010090
  10. Muir CS, Nectoux J, Staszewski J (1991). The epidemiology of prostatic cancer. Geographical distribution and time-trends. Acta Oncol, 30, 133-40. https://doi.org/10.3109/02841869109092336
  11. Potosky AL, Kessler L, Gridley G, et al (1990). Rise in prostatic cancer incidence associated with increased use of transurethral resection. J Natl Cancer Inst, 82, 1624-8. https://doi.org/10.1093/jnci/82.20.1624
  12. Potosky AL, Miller BA, Albertsen PC et al (1995). The role of increasing detection in the rising incidence of prostate cancer. JAMA, 273, 548-52. https://doi.org/10.1001/jama.1995.03520310046028
  13. Yavuz SS, Dilek S, Aye TS, et al (2008). Dietary agents in prevention of prostate cancer. Asian Pac J Cancer Prev, 9, 183-6.

Cited by

  1. Bisphosphonates for Osteoporosis in Nonmetastatic Prostate Cancer Patients Receiving Androgen-deprivation Therapy: A Systematic Review and Meta-analysis vol.14, pp.5, 2013, https://doi.org/10.7314/APJCP.2013.14.5.3337
  2. Laser Induced Fluorescence Studies of Blood Plasma and Tumor Tissue of Men with Prostate Tumors vol.05, pp.11, 2014, https://doi.org/10.4236/jct.2014.511107
  3. Histopathologic Characterization of Prostate Diseases in Madinah, Saudi Arabia vol.15, pp.10, 2014, https://doi.org/10.7314/APJCP.2014.15.10.4175
  4. Frequency of Unnecessarily Biopsies among Patients with Suspicion of Prostate Cancer in Syrian Men vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5967
  5. Oral exposure to hexavalent chromium through drinking water and urologic morbidity in an industrial area of Greece vol.23, pp.5, 2015, https://doi.org/10.1007/s10389-015-0681-8
  6. Diagnostic and treatment factors associated with poor survival from prostate cancer are differentially distributed between regional and metropolitan Victoria, Australia vol.16, pp.1, 2016, https://doi.org/10.1186/s12894-016-0172-4
  7. Prostate Cancer in Iran: Trends in Incidence and Morphological and Epidemiological Characteristics vol.17, pp.2, 2016, https://doi.org/10.7314/APJCP.2016.17.2.839